Orna Therapeutics

#Advanced Therapies #Autoimmune disease #Cell therapy #Eli Lilly #Orna Therapeutics

Lilly to advance cell therapies after Orna acquisition 

Eli Lilly has acquired biotech company Orna Therapeutics to further develop its pipeline of cell therapies in autoimmune diseases.  Orna is advancing a new class of therapeutics utilising engineered circular RNA paired with novel lipid nanoparticles to allow the patient’s own body to generate cell therapies that can treat underlying disease.  The company’s lead programme,… Read More

#Business & Investment #News

#Collaboration #Gene therapy #Lipid based nanoparticle (LNP) #Orna Therapeutics #Vertex

Vertex signs multimillion dollar deal with Orna Therapeutics

Vertex Pharmaceuticals and Orna Therapeutics have announced plans to partner on gene therapies for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).  The three-year strategic research collaboration will utilise Orna’s lipid nanoparticle (LNP) delivery solutions.  In return Orna will receive upfront payments of $65 million, including an investment in… Read More

#Business & Investment #News #Trending News